Mitral regurgitation (MR) is the most frequent type of valve heart disease, and the COAPT has shown that edge-to-edge with guideline directed medical treatment (GDMT) at maximal tolerated dose (MTD) is superior to medical treatment alone. However, we did not have a score to predict patient evolution when treated with this strategy. Researchers analyzed the<a href="https://solaci.org/en/2022/10/14/a-simple-score-for-mortality-and-cardiac-failure-after-edge-to-edge-with-mitraclip/" title="Read more" >...</a>
The New Sirolimus Eluting Balloons Are Also Effective
The technological development of drug eluting stents has allowed us to treat increasingly complex patients, with around 10% stenosis and using more, and longer stents. This situation generates a great challenge: keep using stents or use paclitaxel coated balloons (PCB). At present, there are sirolimus drug coated balloons (SCB), but we do not have enough<a href="https://solaci.org/en/2022/10/11/the-new-sirolimus-eluting-balloons-are-also-effective/" title="Read more" >...</a>
Use of OCT FFR on ACS Clinical Outcomes
Patients undergoing acute coronary syndrome (ACS) benefit from percutaneous coronary intervention (PCI). At present, there is no question about this. However, residual ischemia after PCI is associated with a worse prognosis. Angiography studies and intravascular imaging are useful to assess post intervention outcomes, but they are limited when it comes to the physiological assessment of<a href="https://solaci.org/en/2022/10/05/use-of-oct-ffr-on-acs-clinical-outcomes/" title="Read more" >...</a>
Clinical Results of IVUS-Guided Drug-Eluting Stent Implantation in Femoropopliteal Disease
Endovascular treatment of femoropopliteal lesions has become the first-line treatment due to the development of devices that decrease the restenosis rate. Recently, the IMPERIAL study showed greater patency at 1 year and greater freedom from clinically guided revascularization at 2 years in favor of the ELUVIA stent (paclitaxel-eluting fluoropolymer, FP-DES) compared with the ZILVER PTX<a href="https://solaci.org/en/2022/08/23/clinical-results-of-ivus-guided-drug-eluting-stent-implantation-in-femoropopliteal-disease/" title="Read more" >...</a>
IN.PACT Global: Follow Up of Real-Life Patient in Femoropopliteal Territory
Drug coated balloons (DCB) emerged as an innovative treatment approximately 10 years ago. Since then, numerous randomized studies have shown their effectiveness and benefit in femoropopliteal territory, and even though the use of paclitaxel coated balloons has been called into question, a retrospective study including 168,553 patients was able to show paclitaxel coated balloons were<a href="https://solaci.org/en/2022/06/27/in-pact-global-follow-up-of-real-life-patient-in-femoropopliteal-territory/" title="Read more" >...</a>
Using Biolimus-Coated Balloons for Treating Small-Vessel Disease Yields Promising Results
Drug-eluting balloons have demonstrated safety and effectiveness in the treatment of small-vessel coronary artery disease and in-stent restenosis. However, randomized studies were performed using paclitaxel. Several studies have shown that using biolimus, a semisynthetic analog of sirolimus, optimizes drug delivery in both stents and balloons. The aim of this randomized, multicenter study was to evaluate<a href="https://solaci.org/en/2022/06/13/using-biolimus-coated-balloons-for-treating-small-vessel-disease-yields-promising-results/" title="Read more" >...</a>
Revascularization Using DES in Infrapopliteal Disease: Meta-Analysis and Change of Paradigm?
Peripheral vascular disease (PVD) has been under-studied and under-recognized in comparison with ischemic heart disease and stroke, despite its well-known impact on quality of life and its associated morbidity and mortality. According to a systematic review, it was estimated that in 2015 about 238 million people globally had PVD. This number is on the rise.<a href="https://solaci.org/en/2022/06/01/revascularization-using-des-in-infrapopliteal-disease-meta-analysis-and-change-of-paradigm/" title="Read more" >...</a>
Drug-Eluting Balloons Find Their Niche
According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a<a href="https://solaci.org/en/2021/10/13/drug-eluting-balloons-find-their-niche/" title="Read more" >...</a>
ELUVIA: DES in Complex Femoropopliteal Lesions
Paclitaxel-eluting stent Eluvia showed promising results after two years with a revascularization freedom rate of 80% despite the fact that these were complex femoropopliteal lesions. As the safety of paclitaxel-eluting devices becomes more consistent, more studies on its efficacy are being published. Back in 2018, the safety of paclitaxel-eluting balloons and stents was under scrutiny<a href="https://solaci.org/en/2021/06/12/eluvia-des-in-complex-femoropopliteal-lesions/" title="Read more" >...</a>
ACC 2021 | VOYAGER PAD: Usefulness of Rivaroxaban After Peripheral Angioplasty
Patients with peripheral vascular disease who undergo angioplasty in the lower limbs find benefit from treatment with rivaroxaban, according to the VOYAGER PAD study, presented at the scientific sessions of the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JACC. Patients with said disease present a higher risk of ischemic events not<a href="https://solaci.org/en/2021/05/21/acc-2021-voyager-pad-usefulness-of-rivaroxaban-after-peripheral-angioplasty/" title="Read more" >...</a>